NFE2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4264977	0.45	2/20
SCHEMBL1493355	0.76	1/20
SCHEMBL1493588	0.74	1/20
SCHEMBL1493342	0.68	1/20
SCHEMBL1493561	0.68	1/20
SCHEMBL1493425	0.67	1/20
SCHEMBL1493585	0.66	1/20
SCHEMBL1493291	0.66	1/20
SCHEMBL1493384	0.66	1/20
SCHEMBL1493403	0.65	1/20
SCHEMBL1493451	0.65	1/20
SCHEMBL1493514	0.65	1/20
SCHEMBL12682735	0.64	1/20
SCHEMBL1493606	0.62	1/20
SCHEMBL1493509	0.62	1/20
SCHEMBL1493552	0.58	1/20
SCHEMBL14026830	0.58	1/20
SCHEMBL1612575	0.58	1/20
SCHEMBL1409741	0.56	1/20
SCHEMBL1821555	0.56	1/20

Clinical trials — most relevant to NFE2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients	PHASE4	UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers	PHASE2	RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy	PHASE2	RECRUITING
Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes	PHASE2	COMPLETED
Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis.	PHASE2	COMPLETED
Broccoli Sprout Extracts Trial to See if NRF2 is Enhanced by Sulforaphane Treatment in Patients With COPD	PHASE2	COMPLETED
Simvastatin in Secondary Progressive Multiple Sclerosis	PHASE2	COMPLETED
Effect of Oral Supplementation With Curcumin in Patients With Proteinuric Diabetic Kidney Disease	PHASE2	UNKNOWN
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS	PHASE1/PHASE2	COMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)	nan	RECRUITING
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure	nan	UNKNOWN
Cell Signaling and Resistance to Oxidative Stress: Effects of Aging and Exercise	nan	COMPLETED
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED
Human Study of Hydroxytyrosol on Phase II Enzymes in Healthy Subjects	nan	COMPLETED
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
Polymorphism of Estrogen Genes in Stroke	nan	UNKNOWN
Treatment Strategy to Enhance Nrf2 Signaling in Older Adults	nan	COMPLETED
Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders	nan	RECRUITING
Effects of Gallotannins on the Gut Microbiome and How it Affects Inflammatory Markers Among Obese Individuals.	nan	ACTIVE_NOT_RECRUITING
Targeting Oxidative Stress to Prevent Vascular and Skeletal Muscle Dysfunction During Disuse	nan	ACTIVE_NOT_RECRUITING
Involvement of Pollutants in Atopic Dermatitis and Psoriasis	nan	UNKNOWN
ADAPT: Efficacy of a Dietary Supplement During and After Exercise	nan	COMPLETED
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient	nan	RECRUITING
Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients	nan	RECRUITING
Mild Intermittent Hypoxia and Its Multipronged Effect on Sleep Apnea	nan	RECRUITING
Effect of Protein on Endoplasmic Reticulum Stress	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NFE2 binder may also engage these)

Protein	Name	Similarity
Q6AYT2	—	1.000	Q6AYT2 →
Q07279	—	1.000	Q07279 →
Q5EAD3	—	1.000	Q5EAD3 →
Q60795	—	0.990	Q60795 →
O54968	—	0.990	O54968 →
Q6PZD9	—	0.989	Q6PZD9 →
O95238	—	0.988	O95238 →
Q61501	—	0.988	Q61501 →
Q5NUA6	—	0.988	Q5NUA6 →
Q14209	—	0.988	Q14209 →
P12525	—	0.988	P12525 →
NR4A1	Nuclear receptor subfamily 4immunitygroup A member 1	0.987	landscape →
Q61985	—	0.987	Q61985 →
Q9BQI7	—	0.987	Q9BQI7 →
Q15744	—	0.987	Q15744 →
O43889	—	0.986	O43889 →
O77728	—	0.986	O77728 →
Q8AXV5	—	0.986	Q8AXV5 →
P0C0N9	—	0.986	P0C0N9 →
Q00322	—	0.986	Q00322 →
Q80Y50	—	0.986	Q80Y50 →
A0JPN4	—	0.986	A0JPN4 →
Q9H8N7	—	0.986	Q9H8N7 →
Q61817	—	0.986	Q61817 →
P12813	—	0.986	P12813 →
Q8K3T3	—	0.986	Q8K3T3 →
POU5F1	POU domain, class 5, transcription factor 1	0.985	landscape →
Q01094	—	0.985	Q01094 →
Q32NH9	—	0.985	Q32NH9 →
O18805	—	0.985	O18805 →